BRU · UCB.BR
UCB S.A.
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
Loading market information…
BRU · ALEMS.BR · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 02:19 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
European Medical Solutions’s quoted price sits in the lower half of its reported 52-week range, 34.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow European Medical Solutions’s reporting calendar.
THE COMPANY BEHIND THE TICKER
European Medical Solutions engages in the design, development, and manufacturing of medical imaging systems for digital radiology and bone densitometry in Belgium and internationally. It offers R/F solutions, including PLATINUM NEO, a solution that revolutionizes the R/F workflow through an interface and AI-powered image processing; OPTIMA, a performance remote-controlled table designed to provide, imaging solution for radiography and fluoroscopy examinations; bone densitometry and body composition analysis equipment; chest and bone rooms, such as floor and ceiling tube stands; ambulatory radiography equipment; retrofit kits; C-ARM mobile operating room solutions; and mammography solutions. The company was formerly known as DMS Imaging SA and changed its name to European Medical Solutions in June 2024. DMS Imaging SA was founded in 1979 and is headquartered in Ixelles, Belgium. European Medical Solutions operates as a subsidiary of Diagnostic Medical Systems S.A.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:06 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€280.00+€9.50 (+3.51%)
UCB S.A.’s quoted price sits in the upper half of its reported 52-week range, 3.28% below the high.
€227.60+€6.80 (+3.08%)
Financière de Tubize S.A.’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
€28.90+€0.34 (+1.19%)
Lakefront Biotherapeutics’s quoted price sits in the upper half of its reported 52-week range, 5.92% below the high.
€23.40-€0.45 (-1.89%)
Fagron N.V.’s quoted price sits in the upper half of its reported 52-week range, 7.51% below the high.
€16.46+€0.12 (+0.73%)
Ion Beam Applications S.A.’s quoted price sits in the upper half of its reported 52-week range, 7.32% below the high.
$7.95-$0.01 (-0.13%)
AgomAb Therapeutics N.V. American Depositary Shares’s quoted price sits in the lower half of its reported 52-week range, 55.39% below the high.
€3.86+€0.21 (+5.75%)
Hyloris Pharmaceuticals S.A.’s quoted price sits in the lower half of its reported 52-week range, 54.05% below the high.
$0.89-$0.01 (-1.34%)
Nyxoah S.A.’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
